Roche terminates partnership with Atea to develop Covid-19 antiviral drug
The licenses Roche received under the collaboration will be returned to Atea, which will conduct clinical development and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Nov 21
The licenses Roche received under the collaboration will be returned to Atea, which will conduct clinical development and…
16 Nov 21
AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A), jointly developed by AstraZeneca and…
16 Nov 21
Health Canada authorisation was based on scientific evidence shared by Moderna, including data from the Phase 2 clinical…
15 Nov 21
The EC approval follows EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation to authorise two Covid-19…
12 Nov 21
Ronapreve and Regkirona are the first monoclonal antibody medicines to receive a positive opinion from the CHMP for…
12 Nov 21
The 77.8% vaccine efficacy was based on 130 confirmed cases, where 24 cases were observed in the vaccine…
11 Nov 21
The collaboration will leverage Novome’s GEMMs platform for growing therapeutically engineered bacteria in the human gut
10 Nov 21
Under the terms of the agreement, Biohaven will continue to solely market the migraine drug rimegepant in the…
10 Nov 21
The procurement is subject to US Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) or approval of…
09 Nov 21
The financing from Blackstone will support Autolus’ clinical development of obe-cel for relapsed / refractory adult ALL and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates